Condition: Acute Respiratory Distress Syndrome · Extracorporeal Membrane Oxygenation Complication · Sponsor: Assistance Publique - Hôpitaux de Paris
The CALMDOWN trial is a prospective, open-label, multicenter, comparative, controlled trial randomizing patients who received near apneic ventilation vs usual care on ECMO (ultra-protective lung ventilation). The study goal is to investigate the benefit of early apneic ventilation in the most severe forms of acute respiratory distress syndrome (ARDS) rescued by ECMO. Indeed, our hypothesis is that that early (near) apneic ventilation on venovenous ECMO for severe ARDS can enhance ventilator injury prevention and therefore reduce ECMO duration and mortality at Day 60.
This description comes directly from the study's public registry record.
Matthieu SCHMIDT, MD · 01 42 16 29 37 · matthieu.schmidt@aphp.fr
Always discuss trial participation with your own doctor first.
| Avicenne Hospital | Bobigny, France | Recruiting |
| Haut Levèque Hospital - CHU Bordeaux | Bordeaux, France | Recruiting |
| Henri Mondor Hospital | Créteil, France | Recruiting |
| Croix-Rousse Hospital - HCL | Lyon, France | Recruiting |
| North Hospital - APHM | Marseille, France | Recruiting |
| Mercy Hospital - CHR Metz | Metz, France | Recruiting |
| Brabois Hospital - CHRU Nancy | Nancy, France | Recruiting |
| CHU Orléans | Orléans, France | Recruiting |
| Pitié-Salpêtrière Hospital | Paris, France | Recruiting |
| Pontchaillou Hospital - CHU Rennes | Rennes, France | Recruiting |
| CHU Tours | Tours, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06814340